MN HOUSE RESEARCH

Chapter 44

2019 Regular Session

Subject Pharmacy Licensure and Peritoneal Dialysis

Analyst Randall Chun

Date July 8, 2020

Overview

This act exempts from pharmacy licensure requirements manufacturers and other entities that distribute dialysate or devices to perform home peritoneal dialysis on patients with end-stage renal disease, if specified criteria are met.

Summary

Section	Description
1	**Pharmacy licensure requirements.** Amends § 151.19, subd. 1. Provides an exemption from pharmacy licensure requirements for a drug manufacturer, wholesale drug distributor, or a third-party logistics provider, that distributes dialysate or devices to perform home peritoneal dialysis on patients with end-stage renal disease, if: 1) the manufacturer or its agent leases or owns the facility from which the dialysate or devices will be delivered; 2) the dialysate is comprised of dextrose or icodextrin and has been approved by the Food and Drug Administration; 3) the dialysate is stored and delivered in original, sealed, and unopened packaging; 4) the dialysate or devices are delivered only upon receipt of a physician's order by a pharmacy, and the prescription is reviewed and processed by a pharmacist meeting specified criteria; 5) records and other information are maintained by the manufacturer for a minimum of three years and made available to the board upon request; and 6) the manufacturer or agent delivers the dialysate or devices directly to the patient or patient's designee, for self-administration of the dialysis therapy; or a health care provider or institution, for administration or delivery of dialysis therapy to the patient.